Meeting
2023 ASCO Annual Meeting
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
Authors
Ömür Gökmen Sevindik
Istanbul Medipol University, International School of Medicine, Istanbul, Turkey
Ömür Gökmen Sevindik , Chang Chen , Jing Yang , Mohammed Z.H. Farooqui , Ewa Paszkiewicz-Kozik
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Other Lymphoma
Clinical Trial Registration Number
NCT05624554
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7594)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7594
Abstract #
TPS7594
Poster Bd #
137b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 3 zanubrutinib (BGB‑3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
First Author: Peter Hillmen
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2023 ASCO Annual Meeting
AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.
First Author: Rashmi Khanal
Poster
2023 ASCO Annual Meeting
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.
First Author: Michael Dickinson